Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Beta Bionics Inc’s stock clocked out at $16.89, up 10.39% from its previous closing price of $15.3. In other words, the price has increased by $10.39 from its previous closing price. On the day, 0.75 million shares were traded. BBNX stock price reached its highest trading level at $17.0 during the session, while it also had its lowest trading level at $15.22.
Ratios:
To gain a deeper understanding of BBNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.79 and its Current Ratio is at 14.68. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $26.
On June 12, 2025, Lake Street started tracking the stock assigning a Buy rating and target price of $30.
On May 30, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $20.Wolfe Research initiated its Outperform rating on May 30, 2025, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 19 ’25 when Hopman Mark sold 16,158 shares for $16.61 per share. The transaction valued at 268,376 led to the insider holds 34,132 shares of the business.
Feider Stephen sold 5,587 shares of BBNX for $95,172 on Aug 19 ’25. The Chief Financial Officer now owns 45,503 shares after completing the transaction at $17.03 per share. On Aug 19 ’25, another insider, Feider Stephen, who serves as the Officer of the company, bought 5,587 shares for $17.03 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBNX now has a Market Capitalization of 734209984 and an Enterprise Value of 491177408. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.41 while its Price-to-Book (P/B) ratio in mrq is 2.43. Its current Enterprise Value per Revenue stands at 7.034 whereas that against EBITDA is -9.22.
Stock Price History:
Over the past 52 weeks, BBNX has reached a high of $24.50, while it has fallen to a 52-week low of $8.89. The 50-Day Moving Average of the stock is 10.18%, while the 200-Day Moving Average is calculated to be 7.99%.
Shares Statistics:
It appears that BBNX traded 581.94K shares on average per day over the past three months and 696020 shares per day over the past ten days. A total of 43.47M shares are outstanding, with a floating share count of 32.74M. Insiders hold about 24.68% of the company’s shares, while institutions hold 87.75% stake in the company. Shares short for BBNX as of 1753920000 were 4187831 with a Short Ratio of 7.20, compared to 1751241600 on 4903188. Therefore, it implies a Short% of Shares Outstanding of 4187831 and a Short% of Float of 10.879999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.34 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.76 and -$2.24 for the fiscal current year, implying an average EPS of -$2.03. EPS for the following year is -$1.85, with 5.0 analysts recommending between -$1.52 and -$2.03.
Revenue Estimates
For the next quarter, 8 analysts are estimating revenue of $26.4M. There is a high estimate of $27.65M for the next quarter, whereas the lowest estimate is $24.3M.
A total of 8 analysts have provided revenue estimates for BBNX’s current fiscal year. The highest revenue estimate was $92.86M, while the lowest revenue estimate was $88.8M, resulting in an average revenue estimate of $91.19M. In the same quarter a year ago, actual revenue was $65.12MBased on 8 analysts’ estimates, the company’s revenue will be $122.03M in the next fiscal year. The high estimate is $132.79M and the low estimate is $113.1M.
